RT Journal Article
SR Electronic
T1 Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring
JF American Society for Clinical Laboratory Science
JO Clin Lab Sci
FD American Society of Chemistry and Laboratory Science
SP 218
OP 223
DO 10.29074/ascls.28.4.218
VO 28
IS 4
A1 Melissa L. White
YR 2015
UL http://hwmaint.clsjournal.ascls.org/content/28/4/218.abstract
AB Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications. The newer drugs have a more specific mechanism of action for inhibiting coagulation and do not require continuous monitoring like their predecessor. Their efficacy and safety has been proven, but problems arise in the clinical laboratory with developing accurate procedures to measure the therapy when needed. Methods being used are the prothrombin time and anti-factor Xa chromogenic assay which require calibration with the drug being measured. The prothrombinase-induced clotting test shows promise as a measure for Xa inhibitors. The article reviews the oral Factor Xa inhibitor's clinical usefulness, effects on current laboratory coagulation tests and methods for measuring their anticoagulant activity.ABBREVIATIONS: CYP – cytochrome; DOAC – direct oral anticoagulant; DVT – deep venous thrombosis; INR – international normalized ratio; PE – pulmonary embolism; PiCT – prothrombinase-induced clotting time; PT – prothrombin time; APTT – activated partial thromboplastin time.